Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci.

Dylan M Glubb | Sharon E Johnatty | Michael C J Quinn | Tracy A O'Mara | Jonathan P Tyrer | Bo Gao | Peter A Fasching | Matthias W Beckmann | Diether Lambrechts | Ignace Vergote | Digna R Velez Edwards | Alicia Beeghly-Fadiel | Javier Benitez | Maria J Garcia | Marc T Goodman | Pamela J Thompson | Thilo Dörk | Matthias Dürst | Francesmary Modungo | Kirsten Moysich | Florian Heitz | Andreas du Bois | Jacobus Pfisterer | Peter Hillemanns | AGO Study Group | Beth Y Karlan | Jenny Lester | Ellen L Goode | Julie M Cunningham | Stacey J Winham | Melissa C Larson | Bryan M McCauley | Susanne Krüger Kjær | Allan Jensen | Joellen M Schildkraut | Andrew Berchuck | Daniel W Cramer | Kathryn L Terry | Helga B Salvesen | Line Bjorge | Penny M Webb | Peter Grant | Tanja Pejovic | Melissa Moffitt | Claus K Hogdall | Estrid Hogdall | James Paul | Rosalind Glasspool | Marcus Bernardini | Alicia Tone | David Huntsman | Michelle Woo | Aocs Group | Anna deFazio | Catherine J Kennedy | Paul D P Pharoah | Stuart MacGregor | Georgia Chenevix-Trench
Oncotarget | 2017

We previously identified associations with ovarian cancer outcome at five genetic loci. To identify putatively causal genetic variants and target genes, we prioritized two ovarian outcome loci (1q22 and 19p12) for further study. Bioinformatic and functional genetic analyses indicated that MEF2D and ZNF100 are targets of candidate outcome variants at 1q22 and 19p12, respectively. At 19p12, the chromatin interaction of a putative regulatory element with the ZNF100 promoter region correlated with candidate outcome variants. At 1q22, putative regulatory elements enhanced MEF2D promoter activity and haplotypes containing candidate outcome variants modulated these effects. In a public dataset, MEF2D and ZNF100 expression were both associated with ovarian cancer progression-free or overall survival time. In an extended set of 6,162 epithelial ovarian cancer patients, we found that functional candidates at the 1q22 and 19p12 loci, as well as other regional variants, were nominally associated with patient outcome; however, no associations reached our threshold for statistical significance (p<1×10-5). Larger patient numbers will be needed to convincingly identify any true associations at these loci.

Pubmed ID: 29029385 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: Cancer Research UK, United Kingdom
    Id: 10124
  • Agency: NCI NIH HHS, United States
    Id: P50 CA159981
  • Agency: NCI NIH HHS, United States
    Id: R01 CA058598
  • Agency: NCATS NIH HHS, United States
    Id: UL1 TR000124
  • Agency: NCI NIH HHS, United States
    Id: P50 CA105009
  • Agency: NCI NIH HHS, United States
    Id: K07 CA080668
  • Agency: NCI NIH HHS, United States
    Id: U19 CA148537
  • Agency: NCI NIH HHS, United States
    Id: R01 CA076016
  • Agency: NCI NIH HHS, United States
    Id: U19 CA148112
  • Agency: NCI NIH HHS, United States
    Id: R01 CA149429
  • Agency: NCI NIH HHS, United States
    Id: U19 CA148065
  • Agency: NCI NIH HHS, United States
    Id: P50 CA136393
  • Agency: NCRR NIH HHS, United States
    Id: M01 RR000056
  • Agency: NCI NIH HHS, United States
    Id: R01 CA095023
  • Agency: NCI NIH HHS, United States
    Id: P30 CA008748
  • Agency: NCI NIH HHS, United States
    Id: R01 CA128978
  • Agency: NCI NIH HHS, United States
    Id: R01 CA054419
  • Agency: NCI NIH HHS, United States
    Id: R01 CA122443
  • Agency: NCI NIH HHS, United States
    Id: P30 CA015083
  • Agency: NCI NIH HHS, United States
    Id: R01 CA126841
  • Agency: Cancer Research UK, United Kingdom
    Id: 10119

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


R Project for Statistical Computing (tool)

RRID:SCR_001905

Software environment and programming language for statistical computing and graphics. R is integrated suite of software facilities for data manipulation, calculation and graphical display. Can be extended via packages. Some packages are supplied with the R distribution and more are available through CRAN family.It compiles and runs on wide variety of UNIX platforms, Windows and MacOS.

View all literature mentions

The Cancer Genome Atlas (tool)

RRID:SCR_003193

Project exploring the spectrum of genomic changes involved in more than 20 types of human cancer that provides a platform for researchers to search, download, and analyze data sets generated. As a pilot project it confirmed that an atlas of changes could be created for specific cancer types. It also showed that a national network of research and technology teams working on distinct but related projects could pool the results of their efforts, create an economy of scale and develop an infrastructure for making the data publicly accessible. Its success committed resources to collect and characterize more than 20 additional tumor types. Components of the TCGA Research Network: * Biospecimen Core Resource (BCR); Tissue samples are carefully cataloged, processed, checked for quality and stored, complete with important medical information about the patient. * Genome Characterization Centers (GCCs); Several technologies will be used to analyze genomic changes involved in cancer. The genomic changes that are identified will be further studied by the Genome Sequencing Centers. * Genome Sequencing Centers (GSCs); High-throughput Genome Sequencing Centers will identify the changes in DNA sequences that are associated with specific types of cancer. * Proteome Characterization Centers (PCCs); The centers, a component of NCI's Clinical Proteomic Tumor Analysis Consortium, will ascertain and analyze the total proteomic content of a subset of TCGA samples. * Data Coordinating Center (DCC); The information that is generated by TCGA will be centrally managed at the DCC and entered into the TCGA Data Portal and Cancer Genomics Hub as it becomes available. Centralization of data facilitates data transfer between the network and the research community, and makes data analysis more efficient. The DCC manages the TCGA Data Portal. * Cancer Genomics Hub (CGHub); Lower level sequence data will be deposited into a secure repository. This database stores cancer genome sequences and alignments. * Genome Data Analysis Centers (GDACs) - Immense amounts of data from array and second-generation sequencing technologies must be integrated across thousands of samples. These centers will provide novel informatics tools to the entire research community to facilitate broader use of TCGA data. TCGA is actively developing a network of collaborators who are able to provide samples that are collected retrospectively (tissues that had already been collected and stored) or prospectively (tissues that will be collected in the future).

View all literature mentions

PLINK (tool)

RRID:SCR_001757

Open source whole genome association analysis toolset, designed to perform range of basic, large scale analyses in computationally efficient manner. Used for analysis of genotype/phenotype data. Through integration with gPLINK and Haploview, there is some support for subsequent visualization, annotation and storage of results. PLINK 1.9 is improved and second generation of the software.

View all literature mentions

IMPUTE2 (tool)

RRID:SCR_013055

A computer program for phasing observed genotypes and imputing missing genotypes.

View all literature mentions

OVCAR-8 (tool)

RRID:CVCL_1629

Cell line OVCAR-8 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

ES-2 (tool)

RRID:CVCL_3509

Cell line ES-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions